Tissue Regenix announced its proposed acquisition of CellRight Technologies for US $30MM. Combined, the companies would offer products for bone and soft tissue regeneration based on CellRight’s human-derived bone grafts and Tissue Regenix’s dCELL® decellularization platform.
CellRight gains access to a new geographies for its products that include Matrix OI Cortical Fibers, MatrixCellect® 100 Demineralized Bone Matrix Crunch and Putty, ConCelltrate™ 100 Demineralized Bone Matrix, etc.
Tissue Regenix would benefit from CellRight’s Texas-based tissue bank as its U.S. base to manufacture products using the dCELL process, which removes DNA and other cellular material from tissue, leaving an acellular tissue scaffold. Earlier this year, the company shared plans for a 2018 launch for dCELL in the U.S. for orthopaedic applications, initially addressing anterior cruciate ligament repair with the OrthoPure® HT decellularized human tendon.
Tissue Regenix announced its proposed acquisition of CellRight Technologies for US $30MM. Combined, the companies would offer products for bone and soft tissue regeneration based on CellRight's human-derived bone grafts and Tissue Regenix’s dCELL® decellularization platform.
CellRight gains access to a new geographies for its...
Tissue Regenix announced its proposed acquisition of CellRight Technologies for US $30MM. Combined, the companies would offer products for bone and soft tissue regeneration based on CellRight’s human-derived bone grafts and Tissue Regenix’s dCELL® decellularization platform.
CellRight gains access to a new geographies for its products that include Matrix OI Cortical Fibers, MatrixCellect® 100 Demineralized Bone Matrix Crunch and Putty, ConCelltrate™ 100 Demineralized Bone Matrix, etc.
Tissue Regenix would benefit from CellRight’s Texas-based tissue bank as its U.S. base to manufacture products using the dCELL process, which removes DNA and other cellular material from tissue, leaving an acellular tissue scaffold. Earlier this year, the company shared plans for a 2018 launch for dCELL in the U.S. for orthopaedic applications, initially addressing anterior cruciate ligament repair with the OrthoPure® HT decellularized human tendon.
Copy to clipboard 
